Evidence map›Paper›PMID 39016609›Full record

ArticleBiotechnology progress

Proteomics-based method to comprehensively model the removal of host cell protein impurities.

Roxana Disela, Daphne Keulen, Eleni Fotou, Tim Neijenhuis, Olivier Le Bussy, Geoffroy Geldhof, Martin Pabst, Marcel Ottens

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Roxana DiselaDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.ORCID 0000-0002-8178-5684
Daphne KeulenDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.ORCID 0000-0001-8086-333X
Eleni FotouDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.
Tim NeijenhuisDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.ORCID 0000-0002-6214-5438
Olivier Le BussyGSK, Technical Research & Development, Rue de l'Institut 89, Rixensart, Belgium.
Geoffroy GeldhofGSK, Technical Research & Development, Rue de l'Institut 89, Rixensart, Belgium.
Martin PabstDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.
Marcel OttensDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.

Funding

GlaxoSmithKline Biologicals S.A.
6 · The paper itself

Abstract

Mechanistic models mostly focus on the target protein and some selected process- or product-related impurities. For a better process understanding, however, it is advantageous to describe also reoccurring host cell protein impurities. Within the purification of biopharmaceuticals, the binding of host cell proteins to a chromatographic resin is far from being described comprehensively. For a broader coverage of the binding characteristics, large-scale proteomic data and systems level knowledge on protein interactions are key. However, a method for determining binding parameters of the entire host cell proteome to selected chromatography resins is still lacking. In this work, we have developed a method to determine binding parameters of all detected individual host cell proteins in an Escherichia coli harvest sample from large-scale proteomics experiments. The developed method was demonstrated to model abundant and problematic proteins, which are crucial impurities to be removed. For these 15 proteins covering varying concentration ranges, the model predicts the independently measured retention time during the validation gradient well. Finally, we optimized the anion exchange chromatography capture step in silico using the determined isotherm parameters of the persistent host cell protein contaminants. From these results, strategies can be developed to separate abundant and problematic impurities from the target antigen.

Indexed as

Escherichia coliProteomicsChromatography, Ion ExchangeDrug ContaminationEscherichia coli ProteinsProteinsEscherichia coli ProteinsProteinsdownstream process developmentE. coli BLRhost cell proteomicsion exchange chromatographyisotherm parameter determinationmechanistic modelingvaccine purification

Identifiers

PMID39016609
PMCPMC11659801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.